ExCellThera announces submission of Drug Master File for

MONTRÉAL, June 17, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules...

Related Keywords

United States ,Canada ,David Millette ,Excellthera Co ,Astellas Institute For Regenerative Medicine ,Astellas Pharma Inc ,Excellthera Inc ,Drug Administration ,Master File ,Cell Stem ,Astellas Pharma ,Astellas Institute ,Regenerative Medicine ,Guy Sauvageau ,Chief Scientific ,Chief Operating ,Drug Master File ,Investigational New Drug Application ,Excellthera ,Biotechnology ,Imf ,Stem Cell ,Small Molecule ,Reagent ,Blood Cancer ,